Genedrive PLC represents a values-driven and customer-centric corporate philosophy. The company is committed to delivering innovative molecular diagnostics solutions that address significant global healthcare challenges. Genedrive PLC focuses on providing efficient, cost-effective, and accurate diagnostic solutions for infectious diseases, pharmacogenetics, and oncology. With a strong emphasis on research and development, Genedrive PLC strives to constantly improve their product offerings and expand their global presence. The company's commitment to quality, integrity, and collaboration sets them apart and drives their mission to improve patient outcomes worldwide.

Genedrive PLC primarily operates in the United Kingdom, Europe, the Middle East, Africa, and the Asia-Pacific region. As a multinational company, Genedrive has a widespread presence, serving customers and collaborating with partners in various countries and regions around the world. With its innovative molecular diagnostics and point-of-care testing solutions, Genedrive has established a strong presence in these markets, delivering healthcare solutions and driving advancements in disease detection, monitoring, and management.

Some significant milestones achieved by Genedrive PLC include the successful development and commercialization of its innovative molecular diagnostics platform, which offers rapid and accurate diagnostic testing for infectious diseases. Genedrive PLC has also secured regulatory approvals for its products in key markets, allowing for global distribution. The company has formed strategic partnerships to expand its reach and enhance product development, such as collaborations with the Foundation for Innovation New Diagnostics and the US Department of Defense. Genedrive PLC has received numerous awards and recognition for its contributions to the field of molecular diagnostics, solidifying its position as a leader in the industry.

Genedrive PLC is a renowned biotech company founded in 2007. With headquarters in Manchester, United Kingdom, the company focuses on the development and commercialization of molecular diagnostic products meant to empower decentralized testing. Genedrive PLC has expertise in infectious diseases and pharmacogenetics, offering innovative solutions to improve patient outcomes globally. Over the years, Genedrive PLC has established itself as a leader in the field, collaborating with various organizations and expanding its product portfolio. The company's dedication to scientific advancements and commitment to improving healthcare make Genedrive PLC a reputable player in the biotech industry.

The main competitors of Genedrive PLC in the market include companies such as Roche Holding AG, Abbott Laboratories, QIAGEN N.V., and Thermo Fisher Scientific Inc. These companies operate in the same industry and offer similar products and services, competing with Genedrive in the field of molecular diagnostics and point-of-care testing. Genedrive PLC aims to differentiate itself through its innovative technology and product portfolio, but it faces competition from these established players in the market.

Genedrive PLC is primarily active in the molecular diagnostics industry.

The business model of Genedrive PLC focuses on providing innovative and versatile molecular diagnostic solutions. Genedrive PLC develops and commercializes portable real-time polymerase chain reaction (PCR) platforms, primarily targeting infectious diseases. By combining rapid, accurate, and accessible testing with advanced molecular diagnostics, Genedrive PLC aims to address global health challenges. With its molecular diagnostics products, the company aims to improve patient outcomes by enabling healthcare professionals to make informed decisions quickly and effectively. Genedrive PLC's business model revolves around empowering diagnostic testing in diverse settings, ultimately contributing to better patient care and public health management.

Det Genedrive P/E-forhold er 0,09.

Genedrive KUV er 0,09.

AlleAktien Kvalitetsscore for Genedrive er 4/10.

Den forventede Genedrive omsætning er 29,45 mio. GBP.

Den forventede Genedrive indtjening er 28,51 mio. GBP.

Genedrive PLC is a rising British company specializing in diagnostics and test solutions for infectious diseases and Hepatitis C virus screening. The company's business concept is based on innovative technologies and products that enable rapid, accurate, and cost-effective identification and quantification of various pathogens. The company is divided into two main areas: Diagnostics and Clinical Applications. In the field of diagnostics, the company offers a wide range of molecular diagnostic tests for bacterial, viral, and parasitic infections, including tests for tuberculosis, malaria, and sexually transmitted diseases. The company's tests are based on the proprietary Genedrive platform, which delivers fast and precise results within 90 minutes. Clinical applications include pharmaceutical research and drug development, as well as personalized medicine. The company offers personalized tests for cancer diagnosis and treatment, as well as genetic tests for predicting disease risks and personalized drug development. Genedrive's products and services are aimed at laboratories, clinical research labs, as well as pharmaceutical and biotech companies worldwide. Another important business segment of Genedrive is Hepatitis C virus screening. The company has developed a hepatitis C virus screening device based on the Genedrive platform. This screening tool allows healthcare providers to diagnose and monitor hepatitis C patients faster and more effectively than conventional tests. Genedrive also offers a wide range of services, including consulting, training, and technology support for its customers. This service area is of great importance to the company as it helps to build long-term customer relationships and loyalty. Genedrive's business model is based on clear differentiation from its competitors through innovative technologies and products that enable the company to be successful in a competitive market. The company also benefits from a strong network of distribution partners in Europe, Asia, and Africa, who support the company in marketing and selling its products and services. Overall, Genedrive's business model is focused on innovation and high quality to meet customer needs. The company has a strong growth strategy that has allowed it to achieve rapid and profitable growth in recent years. With a strong focus on research and development, as well as service and support, Genedrive is well positioned to continue playing a strong role in the diagnostics and testing industry.

Genedrive udbetaler et udbytte på 0 GBP fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Genedrive, eller selskabet udbetaler ikke udbytte.

ISIN'en for Genedrive er GB00B1VKB244.

WKN for Genedrive er A0ML2T.

Tickeren for Genedrive er GDR.L.

I løbet af de sidste 12 måneder betalte Genedrive en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Genedrive sandsynligvis betale en dividende på 0 GBP.

Udbytteafkastet for Genedrive er i øjeblikket .

Genedrive betaler kvartalsvis udbytte. Dette uddeles i månederne .

Genedrive betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 GBP. Dette svarer til et dividendeafkast på 0 %.

Genedrive bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Genedrive fra den 9.9.2024 på 0 GBP, skulle du have haft aktien i din portefølje før ex-datoen den 9.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 9.9.2024.

I løbet af 2023 udbetalte Genedrive 0 GBP i form af dividender.

Udbytterne fra Genedrive udbetales i GBP.